A Phase II Trial of Avelumab, A Fully Humanized Antibody That Targets Cells Expressing PD-L1, in Patients With Recurrent or Progressive Osteosarcoma

Next Previous
Trial Profile

A Phase II Trial of Avelumab, A Fully Humanized Antibody That Targets Cells Expressing PD-L1, in Patients With Recurrent or Progressive Osteosarcoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Avelumab (Primary)
  • Indications Osteosarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 02 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top